Publications (5) View all
-
Article: Secondary haematological malignancies after radioimmunotherapy.
Annals of Hematology 10/2011; 91(6):969. · 2.62 Impact Factor -
Article: Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.
[show abstract] [hide abstract]
ABSTRACT: Alemtuzumab is active in chronic lymphocytic leukaemia (CLL) patients refractory to alkylators and fludarabine. The aim of this study was to determine the efficacy and safety of subcutaneous alemtuzumab at low dose (10 mg three times per week, for 18 weeks) to 49 patients with pre-treated CLL. The overall response rate was 53%, including 27% of complete responses; it was 42% in patients over 70 years, and 54% in the fludarabine-resistant patients. Forty-five percent of the patients with an unfavourable karyotype responded, including 60% of those with the 17p- aberration. After a median follow-up of 25 months, the median overall time to disease progression was 8 months (responders 12 months, non-responders 4 months). The median overall time to alternative treatment was 9 months (responders 17 months, non-responders 6 months) and median overall survival was 30 months. The treatment was well tolerated: grade IV neutropenia was observed in 17%, and cytomegalovirus (CMV) reactivation in 24% of the patients, with no CMV disease. We observed a total of 30 infections (50% during treatment and 50% during the 12-month follow-up), only one-third of which was severe. This study confirms that low-dose subcutaneous alemtuzumab is effective in poor prognosis CLL, and has a particularly favourable toxicity profile.Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 08/2009; 23(11):2027-33. · 8.30 Impact Factor -
Article: Efficacy of photopheresis extracorporeal procedure as single treatment for severe chronic GVHD: A case report.
[show abstract] [hide abstract]
ABSTRACT: Allogeneic hematopoietic stem cell transplantation is the only potentially curative therapeutic option for many malignant and nonmalignant hematologic disorders. Despite this, several factors unfavorably affect the outcome of this procedure and in particular chronic graft-versus-host disease (cGVHD) remains the principal cause of morbidity after allogeneic transplantation. Here we present our experience regarding a patient affected by extensive chronic GVHD (cGVHD) treated only with extracorporeal photopheresis procedure (ECP) as first line treatment. The patient, presenting an high risk myelodysplastic syndrome (MDS), underwent an allogeneic peripheral stem cells transplantation. About 2months after transplantation she experienced a hematological and clinical relapse of MDS. After reinduction therapy with azacitidine she obtained a second complete remission. Because of the risk of relapse related to a strong immunosuppressant therapy and the previous infectious complication, we decided to start a treatment with ECP alone for cGVHD. After six procedure the patient obtained a complete resolution of all signs and symptoms of the cGVHD. This experience may support the possibility to use only an immunomodulant treatment like ECP for the cGVHD, reducing the risk of complications of prolonged immunosuppressant treatment.Transfusion and Apheresis Science 03/2013; · 1.25 Impact Factor -
Article: Successful mobilisation of peripheral blood stem cells in children using plerixafor: a case report and review of the literature.
Blood transfusion = Trasfusione del sangue 10/2012; · 2.10 Impact Factor -
Article: SDF1-3'A gene polymorphism is associated with chronic myeloproliferative disease and thrombotic events.
Clinical Chemistry 01/2006; 51(12):2411-4. · 7.91 Impact Factor
